Navigation Links
Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
Date:10/1/2008

termezzo(R) 3.5 mg or placebo at home, at the time they awakened in the middle of the night and had difficulty returning to sleep. This Phase 3 clinical trial also met its primary endpoint of significantly reducing the time required for the patient to return to sleep versus placebo. After dosing and returning to sleep, patients in the outpatient study who were randomized to Intermezzo(R) also reported fewer subsequent awakenings and less time awake during the remainder of the night. There was no evidence of next day residual sedative effects after middle of the night use of Intermezzo(R) versus placebo.

Glenn A. Oclassen, President and Chief Executive Officer of Transcept, commented, "The submission of the Intermezzo(R) NDA achieves a key milestone for the Transcept team and advances our efforts to gain FDA approval for Intermezzo(R) as the first sleep aid developed specifically to be used in the middle of the night when patients awaken and have difficulty returning to sleep. This NDA submission is the latest in a series of transformative events for Transcept, which have recently included our execution of a definitive merger agreement with Novacea, Inc. Assuming that this proposed merger closes near the end of 2008, Transcept is expected to begin 2009 with an estimated cash balance of $88 to $92 million, which we believe will enable us to carry out our plan to successfully commercialize Intermezzo(R)."

Middle of the Night Awakenings & Intermezzo(R)

According to a recent independent study, conducted by Dr. Maurice Ohayon of the Stanford Sleep Epidemiology Research Center, middle of the night awakening is the most frequently reported insomnia symptom. This study estimates that 35% of American adults experience a middle of the night awakening at least three times per week (Journal of Psychiatric Research, in press).

All of the most commonly prescribed sleep aids are designed to produce approximately seven to eight hours of sleep, and can be
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
2. Critical Pharmaceuticals Enter Sustained Release hGH Arena
3. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
4. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
9. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
10. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
11. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 24, 2014 Research ... addition of the "Global and Chinese Hemodialysis ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. ...
(Date:10/25/2014)... , Oct. 24, 2014  In 2008, two of ... quantities of multiple controlled substances, on a regular basis, ... reported that Dr. Gurney was practicing "all the time" ... one of his employees said that Dr. Gurney was ... of patients." Dr. Gurney,s behavior became increasingly ...
(Date:10/25/2014)... 24, 2014 In conjunction with DURECT Corporation,s ... results press release, you are invited to listen to ... the internet on Monday, November 3, 2014 at 4:30 ... A live audio webcast of the presentation will be ... and clicking "Investor Relations."  If you are unable to ...
Breaking Medicine Technology:Global and Chinese Hemodialysis Concentrates Industry Report 2014 2Global and Chinese Hemodialysis Concentrates Industry Report 2014 3Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 2Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 3DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2
... GLEN ALLEN, Va., Feb. 9, 2011 Rock Creek ... CIGX ) announced that on February 4 a ... Trademark Office ("PTO") for administering a pure form of ... be administered in a composition containing a therapeutically effective ...
... 2011 Cyberonics, Inc. (Nasdaq: CYBX ) today ... third quarter ended January 28, 2011 of its fiscal year ... regular market trading hours.  The company will conduct a conference ... 7:30 AM Central Time (8:30 AM Eastern Time). ...
Cached Medicine Technology:Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 2Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 3Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 4Cyberonics to Report Fiscal Year 2011 Third Quarter Results and Host Conference Call on March 2, 2011 2
(Date:10/25/2014)... Market Research Report on ... is a professional and in-depth market survey ... The report firstly reviews the basic information ... and manufacturing technology. The report then explores ... Diagnostics listing their product specification, capacity, Production ...
(Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
(Date:10/25/2014)... getting the right amount of sleep might raise your ... Those who sleep less or more than the recommended ... prone to developing the chronic condition, which causes inflammation ... that duration and quality of sleep are key factors ... "Both short and long durations of sleep have ...
(Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... tests are developed that spot increased risks for certain cancers, ... about getting screened. But a new study suggests that, ... People who found out their genes doubled their risk of ... risk to get screened. "It didn,t make any difference, ...
(Date:10/22/2014)... On October 22, CBS will air an episode ... fictional and real. The Charles E Holman Morgellons ... advocacy and philanthropy in the battle against Morgellons Disease, ... impart truth and clarity about this misunderstood and routinely ... about Morgellons Disease (MD) and most people ...
Breaking Medicine News(10 mins):Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... Eric ... web seminar hosted by The Center for Business Intelligence. Tools and real-world examples ... improve the effectiveness and efficiency of their own marketing programs. , ... Waltham, MA (PRWEB) October 28, ...
... the needs of patients and their families has several ... helping to stem the increasing costs of medical errors ... are turning to implementation of patient- and family-centered care ... , The Institute for Family-Centered Care defines PFCC ...
... Michael Feiz , lead surgeon at the Beverly Hills Comprehensive Weight ... than any other doctor. For overweight Los Angeles residents, ... been looking for to shed the unhealthy weight and return to ... Lap Band surgery has the added benefit of enabling the ...
... , WASHINGTON, Oct. 27 The St. Louis Cardinals, new ... as hitting coach sends a message to all baseball and ... CONGRESS INVESTIGATES ," former White House drug policy spokesman Bob ... batters? Grab the drugs? When McGwire used Andro (Androstenedione), now ...
... at the Obesity Society 27th Annual Meeting, shows that ... not as hungry when they were taught how to ... satiating snack of peanuts or peanut butter. These changes ... This study group, which received nutrition education, a snack ...
... methods in a few years , TUESDAY, Oct. 27 (HealthDay ... are equally reliable in screening for cervical cancer, a new ... testing has all but replaced the traditional Pap test, but ... according to Dr. Mark Schiffman, a senior investigator at the ...
Cached Medicine News:Health News:5 Steps to Pharmaceutical Marketing Happiness 2Health News:UHC Benchmarking Project Focuses on Patient- and Family-Centered Care in Academic Medical Centers 2Health News:UHC Benchmarking Project Focuses on Patient- and Family-Centered Care in Academic Medical Centers 3Health News:Beverly Hills Doctor (drfeiz.com) Performs the World's Most Lap Band Surgeries 2Health News:Mark McGwire's Message: Cheat, Do Drugs, Cover Up When Congress Investigates, Says Ex-White House Drug Spokesman Bob Weiner; World Series Should Test Both Teams During Games 2Health News:High Nutrient Peanut Snacks Help Overweight Kids Eat Less 2Health News:Old, New Pap Methods Equally Good, Dutch Study Finds 2Health News:Old, New Pap Methods Equally Good, Dutch Study Finds 3
... Upper extremity fixator has been designed to ... by allowing independent movement of its clamp ... goals has been to reduce complexity of ... ease of use. The Hoffmann® II Compact™ ...
The Medium External Fixator has a medium Combination Clamp that connects rod to rod or pin to rod as well as a Medium Multi-Pin Clamp that connects pins to rods allowing parallel pin placement....
The DFS MiniFixator is a lightweight, external device for the treatment of small bone fractures and osteotomies....
... components for individual indications. XCaliber covers a ... an innovative composite plastic material, XCaliber is ... This means it's easier to handle, easier ... patient. ,Comes pre-assembled, packaged sterile, and ready ...
Medicine Products: